Jump to content



Recommended Posts

no - benitec's part of the CoH study is enabling stem and T cell resistance to the HIV virus.


the stem cell transplant, is part of the lymphoma treatment, to replace stem cells that have

been hit by a big dose of chemo used to kill the lymphoma


but what these guys are talking about, without clearer detail, seems to have a lot of '099

about it

Link to comment
Share on other sites

  • Replies 10k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

here's my Friday morning long shot piece of speculation:


maybe Krieg has stepped back from synthetic RNAi, thrown an antisense baulk step, and

is about to move toward gene therapy flavoured RNAi.


there seems to be a hell of a lot of interest, and increasingly more positive news in gene therapy

of late, and it sure has lost the bad karma it had a few years back. And ddRNAi has regained

its lustre.

Link to comment
Share on other sites

maybe the UK PO pr today hints at an answer to your question Buda.

One thing is certain, some body in UK sees a monetary threat from the

Graham patent.


And the reason it's taken since 2003 to instigate the action (and thus pay lawyers..)

maybe has been advised by this Nature article way back (and Dirk a few times):


Patent disputes haven't materialized in the RNAi field yet, but once products near the market, it might be a different story. Charlie Schmidt investigates.




Trouble for the opposition is Graham IP is proving very durable. this UK effort seems to me

as hopes were pinned on Benitec not surving '099 re-exam. Oops. Quick roll plan B out..

Link to comment
Share on other sites

Application Number: 90/007,247 Customer Number:- Filing or 371 ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚© Date: 10-04-2004 Status:

Reexam Terminated -- Notice of Intent to Issue a Reexamination Certificate Mailed

Application Type: Re-Examination Status Date:11-05-2010 Examiner Name: PONNALURI, PADMASHRI Location:

"opens new window"


http://portal.uspto.gov/external/PA_PeaiPair/img/tabs/image16on.gifELECTRONIC Group Art Unit: 3991 Location Date:- Confirmation Number: 6310 Earliest Publication No:- Attorney Docket Number: 0687/74768 Earliest Publication Date:- Class / Subclass: 800/008 Patent Number:- First Named Inventor: 6573099 Issue Date of Patent:-



Link to comment
Share on other sites

Lol, we are in the wrong business. There seems to be a thriving "cottage industry" involved with attacking and defending the Graham '099 and derivatives at the patent office.


This action, in the UK, is not a good reason to sell Buda.


The Graham '099 (and the wider CSIRO/Benitec familiy) are the most cohesive RNAi patent estate. The industry is finally dawning on the fact that, commercially and technically, ddRNA should be as significant in therapy as it is in research.


The only limiting factor (apart from company finances) is the fact that interest in RNAi has "gone off the boil". This "boom and bust" mentality is common in technology - trace Apple Computer's fortunes , for example.


This interest (and associated money) will return.

Link to comment
Share on other sites

This could be half the reason why PBT have gone in to a halt.


Timely for the patent notice to be put out on our weekend after being redacted the day before. I think we can expect a halt on Monday and transaction on Tuesday. Hopefully it won't be restricted to just BLT or PBT.


Wouldn't that be nice?



Link to comment
Share on other sites

nice find on hot copper by maxinemillion: my guess, probably not for which there is a prize, is this

second generation TT-034 is a ddRNAi molecule, and thus requiring benitec licence for commercialisation.

go tacere!!


BLT own @ 5% of Tacere Therapeutics and are eligible for milestone payments for their HepC agent TT-033. I'm not sure what relevance this new second-generation TT-034 would have for BLT though.




Here is an extract:-


IRS Awards $7M to RNAi, microRNA Firms; Grants Shed Light on Company Pipelines

November 04, 2010

Type size:


+EmailPrinter-friendly versionRSS FeedView on one pageBy Doug Macron


The US government has awarded a group of RNAi and microRNA drug firms more than $7 million in tax-free grants to support their therapeutic development efforts.


The money is being issued through the Qualifying Therapeutic Discovery Project program, which was created earlier this year through the Patient Protection and Affordable Care Act and being funded by the Internal Revenue Service.


And while specific details about the projects being funded by the grants were not provided, the awards do provide some insight into some of the companies' pipelines.




For instance, Tacere Therapeutics received $488,958 in two grants, the first of which supports development of a new treatment for hepatitis C.


The company is already developing an HCV drug called TT-033, which was licensed by Pfizer earlier this year (GSN 2/11/2010). It is an expressed RNAi-based molecule containing shRNAs against three different sites of the hepatitis C virus, and is encapsulated in an adeno-associated virus protein coat. However, the grant supports the development of a new HCV treatment called TT-034, suggesting that Tacere is working on a second-generation version of TT-033.


Since it was founded, Tacere has been tightlipped on any of its pipeline programs beyond TT-033. According to the IRS, however, the firm may have set its sights on eye diseases, as well, because the second grant it received is for an ocular agent called SMK-01/03.


Tacere officials were not available for comment.



Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...